Search Results - "Benkert, Pascal"

Assessing the Relative Importance of Imaging and Serum Biomarkers in Capturing Disability, Cognitive Impairment, and Clinical Progression in Multiple Sclerosis.

Authors: Cagol, Alessandro Benkert, Pascal Schaedelin, Sabine et al.

Source: Advanced Science. 2/18/2026, Vol. 13 Issue 10, p1-15. 15p.

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

Authors: Maceski, Aleksandra Maleska Benkert, Pascal Einsiedler, Maximilian et al.

Source: Brain: A Journal of Neurology; Jul2026, Vol. 149 Issue 7, p2295-2307, 13p

Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin‐related amyloidosis—A Swiss reference center experience.

Authors: Loser, Valentin Benkert, Pascal Vicino, Alex et al.

Source: Journal of the Peripheral Nervous System. Mar2023, Vol. 28 Issue 1, p86-97. 12p.

MultiSCRIPT-Cycle 1—a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial

Authors: Janiaud, Perrine Zecca, Chiara Salmen, Anke et al.

Source: Trials. 9/11/2024, Vol. 25 Issue 1, p1-12. 12p.

Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric Cohort.

Authors: Greselin, Martina Lu, Po-Jui Melie-Garcia, Lester et al.

Source: Bioengineering (Basel). Aug2024, Vol. 11 Issue 8, p858. 13p.

Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis.

Authors: Abdelhak, Ahmed Antweiler, Kai Kowarik, Markus C. et al.

Source: Annals of Clinical & Translational Neurology. Feb2024, Vol. 11 Issue 2, p477-485. 9p.

Transient Global Amnesia (TGA): Is It Really Benign? A Pilot Study on Blood Biomarkers.

Authors: Rossini, Fabio Moser, Tobias Unterhofer, Michael et al.

Source: International Journal of Molecular Sciences. Mar2025, Vol. 26 Issue 6, p2629. 14p.

Escalating to medium‐ versus high‐efficacy disease modifying therapy after low‐efficacy treatment in relapsing remitting multiple sclerosis.

Authors: Müller, Jannis Roos, Izanne Kalincik, Tomas et al.

Source: Brain & Behavior. May2024, Vol. 14 Issue 5, p1-11. 11p.

Development of a risk-tailored approach and dashboard for efficient management and monitoring of investigator-initiated trials.

Authors: Klatte, Katharina Subramaniam, Suvitha Benkert, Pascal et al.

Source: BMC Medical Research Methodology. 4/5/2023, Vol. 23 Issue 1, p1-11. 11p.

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.

Authors: Disanto, Giulio Benkert, Pascal Lorscheider, Johannes et al.

Source: PLoS ONE. 3/31/2016, Vol. 11 Issue 3, p1-13. 13p.

Serum neurofilament light chain as a sensitive biomarker for neuromonitoring during extracorporeal membrane oxygenation.

Authors: Fischer, Stefanie Heubner, Lars May, Stephanie et al.

Source: Scientific Reports. 9/9/2024, Vol. 14 Issue 1, p1-10. 10p.

Combining randomized and non‐randomized data to predict heterogeneous effects of competing treatments.

Authors: Chalkou, Konstantina Hamza, Tasnim Benkert, Pascal et al.

Source: Research Synthesis Methods. Jul2024, Vol. 15 Issue 4, p641-656. 16p.

Longitudinal analyses of serum neurofilament light and associations with obesity indices and bioelectrical impedance parameters.

Authors: Hermesdorf, Marco Leppert, David Maceski, Aleksandra et al.

Source: Scientific Reports. 9/23/2022, Vol. 12 Issue 1, p1-8. 8p.

Concentrations of Serum Brain Injury Biomarkers Following SARS-CoV-2 Infection in Individuals with and without Long-COVID—Results from the Prospective Population-Based COVI-GAPP Study.

Authors: Telser, Julia Grossmann, Kirsten Weideli, Ornella C. et al.

Source: Diagnostics (2075-4418). Jul2023, Vol. 13 Issue 13, p2167. 13p.

Serum neurofilament light chain in functionally relevant coronary artery disease and adverse cardiovascular outcomes.

Authors: Amrein, Melissa Meier, Stephanie Schäfer, Ibrahim et al.

Source: Biomarkers. May2023, Vol. 28 Issue 3, p341-351. 11p.

Factors associated with low health-related quality of life in persons with multiple sclerosis: A quantile-based segmentation approach.

Authors: Iaquinto, Stefania Ineichen, Benjamin Victor Salmen, Anke et al.

Source: PLoS ONE. 11/21/2024, Vol. 19 Issue 11, p1-21. 21p.

Development of an age‐adjusted model for blood neurofilament light chain.

Authors: Harp, Christopher Thanei, Gian‐Andrea Jia, Xiaoming et al.

Source: Annals of Clinical & Translational Neurology. Apr2022, Vol. 9 Issue 4, p444-453. 10p.

Serum neurofilament light and tau as prognostic markers for all-cause mortality in the elderly general population-an analysis from the MEMO study.

Authors: Rübsamen, Nicole Maceski, Aleksandra Leppert, David et al.

Source: BMC Medicine. Dec2021, Vol. 19 Issue 1, p1-10. 10p.

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.

Authors: Barro, Christian Benkert, Pascal Disanto, Giulio et al.

Source: Brain: A Journal of Neurology; Aug2018, Vol. 141 Issue 8, p2382-2391, 10p

Temporal association of sNfL and gad‐enhancing lesions in multiple sclerosis.

Authors: Rosso, Mattia Gonzalez, Cindy T. Healy, Brian C. et al.

Source: Annals of Clinical & Translational Neurology. Jun2020, Vol. 7 Issue 6, p945-955. 11p.